Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.74 AUD -1.69% Market Closed
Market Cap: 2.2B AUD

Relative Value

The Relative Value of one MSB stock under the Base Case scenario is 1.95 AUD. Compared to the current market price of 1.74 AUD, Mesoblast Ltd is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MSB Relative Value
Base Case
1.95 AUD
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
9
Median 3Y
92.2
Median 5Y
122.8
Industry
6.9
Forward
88.2
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-12.5
Industry
23
Forward
-28.3
vs History
vs Industry
Median 3Y
-13.5
Median 5Y
-15.9
Industry
19.7
vs History
vs Industry
Median 3Y
-13
Median 5Y
-14.5
Industry
22.8
vs History
26
vs Industry
27
Median 3Y
1.7
Median 5Y
2
Industry
2.6
vs History
14
vs Industry
6
Median 3Y
96.7
Median 5Y
126.4
Industry
7.4
Forward
92.3
vs History
15
vs Industry
7
Median 3Y
-32.2
Median 5Y
-44.9
Industry
9.3
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-14.5
Industry
4.1
Forward
-24.8
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-14.5
Industry
4.1
Forward
-22.8
vs History
vs Industry
Median 3Y
-14.4
Median 5Y
-15.7
Industry
4.9
vs History
vs Industry
Median 3Y
-14.3
Median 5Y
-15.5
Industry
3.6
vs History
34
vs Industry
41
Median 3Y
1.5
Median 5Y
1.8
Industry
4.7

Multiples Across Competitors

MSB Competitors Multiples
Mesoblast Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Mesoblast Ltd
ASX:MSB
2.2B AUD 255.2 -14 -18.9 -18.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 627 281.5 -164 578.3 -199 850.6 -197 570
US
Abbvie Inc
NYSE:ABBV
331.1B USD 5.8 79.7 15.2 22.5
US
Amgen Inc
NASDAQ:AMGN
154.4B USD 4.5 26 14.1 23.2
US
Gilead Sciences Inc
NASDAQ:GILD
137.5B USD 4.8 23.1 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114B USD 10.3 -115.3 24.5 25.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 034.5 -519.1 -565.3 -550.2
AU
CSL Ltd
ASX:CSL
117.9B AUD 5 27.9 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
52.3B USD 3.7 11.6 10.2 11.5
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60.1 -64.7 -58.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.1B USD 17.1 -148.8 -666.4 -334
P/S Multiple
Revenue Growth P/S to Growth
AU
Mesoblast Ltd
ASX:MSB
Average P/S: 3 148 149.3
255.2
245%
1
FR
Pharnext SCA
OTC:PNEXF
34 627 281.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 034.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.7
5%
0.7
US
S
Seagen Inc
F:SGT
19.6
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
AU
Mesoblast Ltd
ASX:MSB
Average P/E: 33.7
Negative Multiple: -14
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 578.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.7
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.1 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Mesoblast Ltd
ASX:MSB
Average EV/EBITDA: 15.2
Negative Multiple: -18.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 850.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -666.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Mesoblast Ltd
ASX:MSB
Average EV/EBIT: 19.7
Negative Multiple: -18.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 570 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.2
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -334 N/A N/A